Atlantic Trust Group LLC maintained its stake in shares of Quintiles Transitional Holdings Inc. (NYSE:Q) during the 2nd quarter, according to its most recent filing with the SEC. The fund owned 44,310 shares of the medical research company’s stock at the end of the 2nd quarter. Atlantic Trust Group LLC’s holdings in Quintiles Transitional Holdings were worth $3,966,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Shell Asset Management Co. raised its position in shares of Quintiles Transitional Holdings by 1.0% in the 1st quarter. Shell Asset Management Co. now owns 8,769 shares of the medical research company’s stock worth $706,000 after acquiring an additional 83 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Quintiles Transitional Holdings by 0.7% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 11,315 shares of the medical research company’s stock worth $1,013,000 after acquiring an additional 84 shares in the last quarter. Bbva Compass Bancshares Inc. raised its position in shares of Quintiles Transitional Holdings by 4.2% in the 2nd quarter. Bbva Compass Bancshares Inc. now owns 2,204 shares of the medical research company’s stock worth $197,000 after acquiring an additional 88 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Quintiles Transitional Holdings by 3.2% in the 1st quarter. Pacer Advisors Inc. now owns 3,738 shares of the medical research company’s stock worth $301,000 after acquiring an additional 116 shares in the last quarter. Finally, American Century Companies Inc. increased its position in Quintiles Transitional Holdings by 1.1% during the 1st quarter. American Century Companies Inc. now owns 11,719 shares of the medical research company’s stock valued at $944,000 after buying an additional 128 shares in the last quarter. Institutional investors own 91.36% of the company’s stock.
In other Quintiles Transitional Holdings news, insider Kevin C. Knightly sold 19,339 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $99.51, for a total value of $1,924,423.89. Following the sale, the insider now owns 40,650 shares of the company’s stock, valued at $4,045,081.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Cpp Investment Board Private H sold 5,218,245 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $97.33, for a total transaction of $507,891,785.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,363,847 shares of company stock worth $618,573,696. 6.40% of the stock is owned by insiders.
WARNING: “Quintiles Transitional Holdings Inc. (NYSE:Q) Stake Maintained by Atlantic Trust Group LLC” was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/atlantic-trust-group-llc-has-3966000-position-in-quintiles-transitional-holdings-inc-q/1600353.html.
Quintiles Transitional Holdings Inc. (NYSE Q) opened at 95.43 on Friday. The firm’s 50 day moving average price is $93.47 and its 200 day moving average price is $86.36. Quintiles Transitional Holdings Inc. has a 12 month low of $70.10 and a 12 month high of $99.95. The stock has a market cap of $20.66 billion, a price-to-earnings ratio of 276.61 and a beta of 0.63.
Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.04. The business had revenue of $1.97 billion for the quarter, compared to analyst estimates of $1.96 billion. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 14.23%. The business’s revenue was up 68.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.93 earnings per share. On average, equities research analysts predict that Quintiles Transitional Holdings Inc. will post $4.58 EPS for the current fiscal year.
Quintiles Transitional Holdings declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, May 24th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 5.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
A number of research analysts recently weighed in on the company. Barclays PLC reaffirmed an “overweight” rating and set a $98.00 price objective (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research report on Monday, July 17th. Citigroup Inc. lifted their target price on Quintiles Transitional Holdings from $96.00 to $97.00 and gave the stock a “neutral” rating in a report on Monday, August 7th. William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $70.10 to $93.42 in a report on Friday, August 4th. Jefferies Group LLC restated a “hold” rating and issued a $94.00 price target on shares of Quintiles Transitional Holdings in a research note on Friday, August 4th. Finally, BidaskClub downgraded Quintiles Transitional Holdings from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 11th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $90.25.
About Quintiles Transitional Holdings
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with our FREE daily email newsletter.